Keeping Track: Two Novel Migraine Drugs Highlight Busy Week For US FDA Approvals

 
• By Bridget Silverman
  
Generate a summary of this article
Listen to this article
Beta

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image
• Source: Shutterstock

The US Food and Drug Administration’s approval of two novel migraine therapies – Biohaven Pharmaceutical Holding Co. Ltd.'s Nurtec ODT (rimegepant) and Lundbeck Inc.'s Vyepti (eptinezumab-jjmr) – in the space of a week continues the fast expansion of the calcitonin gene-related peptide (CGRP) inhibitor class, which debuted less than two years ago and now counts six FDA-approved agents.

Other highlights of the Center for Drug Evaluation and Research’s activities include approval of a new anti-emetic, Acacia Pharma...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By Saba Afreen

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By Saba Afreen

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>